trending Market Intelligence /marketintelligence/en/news-insights/trending/V-QjYg5l12SiG9zTkDAujA2 content esgSubNav
In This List

Mesoblast, Mallinckrodt sign equity deal; discuss development partnership

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Mesoblast, Mallinckrodt sign equity deal; discuss development partnership

Mallinckrodt Pharmaceuticals is making an equity investment in Mesoblast Ltd.

The parties entered a purchase agreement under which Mallinckrodt will purchase 20.04 million Mesoblast shares at A$1.4761 apiece representing nearly 5% of the company.

The companies are also negotiating a commercial and development partnership to advance two of Mesoblast's drug candidates in phase 3 clinical trial.

MPC-06-ID is being developed for the treatment of chronic back pain due to disc degeneration, while MSC-100-IV is being evaluated as a front-line therapy for children with a certain type of transplant complication.

Mallinckrodt has nine months to conclude negotiations for the rights to both candidates in all territories outside of China and Japan.

As of Dec. 22, US$1 was equivalent to A$1.38.